Quality of Life and Medical Care of Long-term Sarcoma Survivors in Germany (PROSa+)

Sponsor
Technische Universität Dresden
Study ID
NCT07148193
Status
Recruiting
Apply to this trial

Conditions

  • Medical Care
  • Quality of Life (QOL)
  • Sarcoma
  • Survivorship

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • No intervention (observational study) — OTHER
    No intervention (observational study)

Study Details

The study PROSa+ aims to assess patient-reported outcomes (PROs), patient-reported experiences (PREs), and the socioeconomic situation of long-term sarcoma survivors (≥ 5 years post-diagnosis, with or without active disease) in Germany. The mixed-methods research design includes a multicenter observational study with a cross-sectional questionnaire survey involving 1,600 participants (paper, online), qualitative interviews with up to 60 participants, and longitudinal analyses combining data from existing sarcoma registries and the previous PROSa study conducted between 2017 and 2020.

Key Dates

First listed
Aug 29, 2025
Start date
Nov 28, 2025
Status verified
Dec 2025
Primary completion
Sep 30, 2027
Completion
Sep 30, 2027

Study Design

Enrollment
1,600 participants (estimated)

Arms

  • Arm: Sarcoma survivors
    Adults (≥18 years) diagnosed with a sarcoma at least five years prior to study participation, regardless of current disease status, who are treated or receive follow-up care in Germany.

Primary Outcome Measure

Quality of Life (EORTC QLQ-SURV100) [ Time Frame: single-time point (enrollment) ]

Central Contacts

Related Studies